Replimune Group (NASDAQ:REPL) Trading Down 6.3% – Here’s Why

Posted by Geri Gentry on Aug 3rd, 2026

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) dropped 6.3% during trading on Monday . The stock traded as low as $10.13 and last traded at $10.4890. 967,727 shares were traded during trading, a decline of 80% from the average daily volume of 4,886,440 shares. The stock had previously closed at $11.20.

Analyst Ratings Changes

A number of equities analysts recently issued reports on REPL shares. HC Wainwright reissued a “sell” rating on shares of Replimune Group in a report on Monday, April 13th. BMO Capital Markets raised shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price for the company in a report on Tuesday, June 30th. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $9.00 to $12.00 in a research report on Friday. Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday. Finally, Leerink Partners reissued a “market perform” rating and set a $2.00 price objective (down from $11.00) on shares of Replimune Group in a research report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Replimune Group presently has an average rating of “Hold” and a consensus price target of $9.29.

Get Our Latest Stock Report on REPL

Replimune Group Price Performance

The firm has a 50 day moving average price of $9.49 and a 200 day moving average price of $7.38. The company has a quick ratio of 4.79, a current ratio of 4.79 and a debt-to-equity ratio of 0.63. The stock has a market cap of $961.68 million, a P/E ratio of -3.38 and a beta of 0.86.

Replimune Group (NASDAQ:REPL – Get Free Report) last posted its quarterly earnings data on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). On average, analysts forecast that Replimune Group, Inc. will post -2.44 EPS for the current fiscal year.

Insider Activity

In other news, insider Christopher Sarchi sold 12,000 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the sale, the insider directly owned 180,962 shares in the company, valued at $1,672,088.88. This trade represents a 6.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Balyasny Asset Management L.P. lifted its position in shares of Replimune Group by 507.4% in the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after acquiring an additional 2,195,448 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Replimune Group during the fourth quarter worth about $17,568,000. Commodore Capital LP purchased a new stake in shares of Replimune Group during the fourth quarter worth about $13,851,000. EcoR1 Capital LLC bought a new stake in Replimune Group during the 1st quarter valued at approximately $7,650,000. Finally, JPMorgan Chase & Co. raised its stake in Replimune Group by 2,333.6% during the 4th quarter. JPMorgan Chase & Co. now owns 925,173 shares of the company’s stock valued at $8,993,000 after purchasing an additional 887,157 shares during the period. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

(Get Free Report)

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.